BridgeBio Pharma (BBIO) Shares Outstanding (2018 - 2026)

BridgeBio Pharma has reported Shares Outstanding (Entity) for 9 years, with the latest figure at $204.4 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 7.67% year-over-year to $204.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $204.4 million (up 7.67% YoY) and the FY2025 annual result came in at $202.4 million, up 6.49% from the prior year.
• Shares Outstanding (Entity) advanced to $204.4 million in Q1 2026 per BBIO's latest filing, from $202.4 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $204.4 million in Q1 2026 and troughed at $147.7 million in Q1 2022.
• A 5-year average of $177.0 million and a median of $187.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) fell 0.96% in 2022, then increased 16.63% in 2024.
• Over 5 years, Shares Outstanding (Entity) stood at $150.6 million in 2022, then increased by 16.24% to $175.1 million in 2023, then increased by 8.55% to $190.0 million in 2024, then advanced by 6.49% to $202.4 million in 2025, then gained by 1.0% to $204.4 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $204.4 million, $202.4 million, and $200.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.